Fridays Health, a US-based wellness company focused on modern weight loss solutions, announced on Thursday that it has been named a nominee at the World Out of Home Organization's Global Awards.
The recognition was announced during the WOO Annual Congress in Mexico City, where global leaders in out-of-home media recognized the most impactful creative campaigns of the year.
Fridays earned its nomination for an out-of-home (OOH) campaign in downtown Dallas, where a towering 212-foot ad displayed the bold message: 'When your diet hits the wall.'
Created in partnership with digital advertising agency C Squared Social and executed in collaboration with OOH agency OUTFRONT, the campaign was intended to address the frustration many face with crash diets and to position Fridays as a modern, medically guided solution that combines GLP-1 medications with personalized lifestyle and journey support.
Fridays says that it is a digital wellness platform offering personalized weight loss plans supported by GLP-1 medications, medical guidance, and ongoing journey support. The company is focused on sustainable results, accessibility, and helping members take control of their health in a way that feels realistic and empowering.
The World Out of Home Organization Global Awards celebrate innovation and excellence in global out-of-home advertising.
This campaign was also submitted for consideration at the Cannes Lions International Festival, and additional awards submissions are expected this year.
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
WuXi Biologics honoured for water security by CDP
Clario acquires imaging provider NeuroRx
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits